The three musketeers: uniting against CLL

被引:0
|
作者
Kwok, Marwan [1 ,2 ]
Stankovic, Tatjana [1 ]
机构
[1] Univ Birmingham, Birmingham, W Midlands, England
[2] Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England
关键词
OBINUTUZUMAB; VENETOCLAX; RESISTANCE; IBRUTINIB;
D O I
10.1182/blood.2021014826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this issue of Blood , Huber et al(1) present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).
引用
收藏
页码:1264 / 1265
页数:2
相关论文
共 50 条